LIAN Key Statistics, Chart & Performance
The current stock price of LIAN is 0.319 USD. In the past month the price decreased by -93.31%. In the past year, price decreased by -80.9%.
LIAN Latest News, Press Relases and Analysis
LIAN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.76 | 396.82B | ||
| AMGN | AMGEN INC | 15.48 | 182.35B | ||
| GILD | GILEAD SCIENCES INC | 15.19 | 154.37B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.58 | 108.28B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.82 | 79.55B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 888.16 | 59.84B | ||
| INSM | INSMED INC | N/A | 45.04B | ||
| NTRA | NATERA INC | N/A | 32.58B | ||
| BIIB | BIOGEN INC | 10.6 | 26.02B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.2 | 20.68B | ||
| INCY | INCYTE CORP | 15.89 | 20.03B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.22B |
Related stock screener links
About LIAN
Company Profile
LianBio operates as a biopharmaceutical company, which engages in the development and commercialization of medicines for patients with unmet medical needs. The company is headquartered in Princeton, New Jersey and currently employs 163 full-time employees. The company went IPO on 2021-10-28. The firm is focused on developing and commercializing medicines for patients with unmet medical needs, with a focus on in-licensing assets for Greater China and other Asian markets. The company has a pipeline of eight therapeutic candidates across cardiovascular, oncology, ophthalmology, and inflammatory disease indications. Its product candidates include Mavacamten, TP-03, NBTXR3, Infigratinib, BBP-398, Omilancor, NX-13 and LYR-210. Mavacamten is an oral small-molecule allosteric modulator of cardiac myosin, which is approved for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) and is also being studied as a treatment for other diseases of diastolic dysfunction. TP-03 is a topical ophthalmic formulation of lotilaner, that is used for the treatment of demodex blepharitis (DB) and meibomian gland disease (MGD). NBTXR3 is a radio enhancer for the treatment of head and neck cancer and other solid tumors.
Company Info
LIANBIO-ADR
103 Carnegie Center Drive, Suite 309, Suite 215
Princeton NEW JERSEY US
Employees: 163
Phone: 16094862308
LIANBIO-ADR / LIAN FAQ
What does LIAN do?
LianBio operates as a biopharmaceutical company, which engages in the development and commercialization of medicines for patients with unmet medical needs. The company is headquartered in Princeton, New Jersey and currently employs 163 full-time employees. The company went IPO on 2021-10-28. The firm is focused on developing and commercializing medicines for patients with unmet medical needs, with a focus on in-licensing assets for Greater China and other Asian markets. The company has a pipeline of eight therapeutic candidates across cardiovascular, oncology, ophthalmology, and inflammatory disease indications. Its product candidates include Mavacamten, TP-03, NBTXR3, Infigratinib, BBP-398, Omilancor, NX-13 and LYR-210. Mavacamten is an oral small-molecule allosteric modulator of cardiac myosin, which is approved for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) and is also being studied as a treatment for other diseases of diastolic dysfunction. TP-03 is a topical ophthalmic formulation of lotilaner, that is used for the treatment of demodex blepharitis (DB) and meibomian gland disease (MGD). NBTXR3 is a radio enhancer for the treatment of head and neck cancer and other solid tumors.
What is the stock price of LIANBIO-ADR today?
The current stock price of LIAN is 0.319 USD. The price decreased by -8.28% in the last trading session.
What is the dividend status of LIANBIO-ADR?
LIAN does not pay a dividend.
What is the ChartMill technical and fundamental rating of LIAN stock?
LIAN has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is LIANBIO-ADR worth?
LIANBIO-ADR (LIAN) has a market capitalization of 34.47M USD. This makes LIAN a Nano Cap stock.
Can you provide the ownership details for LIAN stock?
You can find the ownership structure of LIANBIO-ADR (LIAN) on the Ownership tab.
LIAN Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to LIAN. When comparing the yearly performance of all stocks, LIAN is a bad performer in the overall market: 99.75% of all stocks are doing better.
LIAN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LIAN. LIAN has a great financial health rating, but its profitability evaluates not so good.
LIAN Financial Highlights
Over the last trailing twelve months LIAN reported a non-GAAP Earnings per Share(EPS) of -0.81. The EPS increased by 28.32% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -33.47% | ||
| ROE | -43.49% | ||
| Debt/Equity | 0 |
LIAN Forecast & Estimates
6 analysts have analysed LIAN and the average price target is 3.98 USD. This implies a price increase of 1147.02% is expected in the next year compared to the current price of 0.319.
For the next year, analysts expect an EPS growth of 16% and a revenue growth -100% for LIAN